These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 7881637)

  • 1. Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma.
    Tanaka N; Sivanandham M; Wallack MK
    J Immunother Emphasis Tumor Immunol; 1994 Nov; 16(4):283-93. PubMed ID: 7881637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model.
    Sivanandham M; Scoggin SD; Tanaka N; Wallack MK
    Cancer Immunol Immunother; 1994 Apr; 38(4):259-64. PubMed ID: 8168121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.
    Jack AM; Aydin N; Montenegro G; Alam K; Wallack M
    J Surg Res; 2007 May; 139(2):164-9. PubMed ID: 17275030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice.
    Sivanandham M; Shaw P; Bernik SF; Paoletti E; Wallack MK
    Cancer Immunol Immunother; 1998 Jul; 46(5):261-7. PubMed ID: 9690454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccinia colon oncolysate immunotherapy for murine hepatic metastases can be modulated with low-dose interleukin-2. Third place winner: Conrad Jobst Award.
    Barnavon Y; Iwaki H; Bash JA; Wallack MK
    Am Surg; 1988 Dec; 54(12):696-701. PubMed ID: 3264127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model.
    Arroyo PJ; Bash JA; Wallack MK
    Cancer Immunol Immunother; 1990; 31(5):305-11. PubMed ID: 2376048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
    McLaughlin JP; Schlom J; Kantor JA; Greiner JW
    Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2.
    Barnavon Y; Iwaki H; Bash JA; Brettschneider F; Hilsenbeck S; Darnell E; Wallack MK
    J Surg Res; 1988 Dec; 45(6):523-30. PubMed ID: 3263545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.
    Kaufman HL; Rao JB; Irvine KR; Bronte V; Rosenberg SA; Restifo NP
    J Immunother; 1999 Nov; 22(6):489-96. PubMed ID: 10570747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active specific immunotherapy of murine colon adenocarcinoma with recombinant vaccinia/interleukin-2-infected tumor cell vaccines.
    Bash JA
    Ann N Y Acad Sci; 1993 Aug; 690():331-3. PubMed ID: 8368746
    [No Abstract]   [Full Text] [Related]  

  • 13. Vaccinia virus-infected C-C36 colon tumor cell lysates stimulate cellular responses in vitro and protect syngeneic Balb/c mice from tumor cell challenge.
    Iwaki H; Barnavon Y; Bash JA; Wallack MK
    J Surg Oncol; 1989 Feb; 40(2):90-6. PubMed ID: 2915544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/macrophage-colony-stimulating-factor-gene-encoded vaccinia virus.
    Ju DW; Cao X; Acres B
    J Cancer Res Clin Oncol; 1996; 122(12):716-22. PubMed ID: 8954168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer.
    Sivanandham M; Stavropoulos CI; Kim EM; Mancke B; Wallack MK
    Cancer Immunol Immunother; 2002 Apr; 51(2):63-71. PubMed ID: 11904730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
    Rao JB; Chamberlain RS; Bronte V; Carroll MW; Irvine KR; Moss B; Rosenberg SA; Restifo NP
    J Immunol; 1996 May; 156(9):3357-65. PubMed ID: 8617961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant vaccinia interleukin-2-infected tumor cell vaccines in immunotherapy of murine colon adenocarcinoma.
    Bash JA
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):269-72. PubMed ID: 8280707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
    Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
    Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
    Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
    Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.